MedTrace Logo

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.

NCT00812981 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2018-08-20

Study results available
· View outcomes & findings →

Summary

This observer-blind study is designed to show the immunological non-inferiority of Thiomersal-free-processed pandemic influenza vaccine as compared to the Thiomersal-containing-processed pandemic influenza vaccine.

Conditions

Interventions

BIOLOGICAL

GSK1562902A

new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm

BIOLOGICAL

GSK1562902A

comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
59 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-11-15
Primary Completion
2009-06-07
Completion
2009-06-07

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00812981 on ClinicalTrials.gov